ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?
Clin Cancer Res 16(13):3319-21 (2010) PMID 20570925
Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM-17 activity in conjunction with current treatments may enhance response rates in advanced CRC patients.
DOI: 10.1158/1078-0432.CCR-10-1059
Version: za2963e q8za1 q8zbe q8zc6 q8zdb q8zed q8zf1 q8zgd